



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Cinoxacin

Cat. No.:	HY-B1085		
CAS No.:	28657-80-9		
Molecular Formula:	C ₁₂ H ₁₀ N ₂ O ₅		
Molecular Weight:	262.22		
Target:	Bacterial; Antibiotic; DNA/RNA Synthesis		
Pathway:	Anti-infection; Cell Cycle/DNA Damage		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 8.33 mg/mL (31.77 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	3.8136 mL	19.0680 mL	38.1359 mL
5 mM	0.7627 mL	3.8136 mL	7.6272 mL
10 mM	0.3814 mL	1.9068 mL	3.8136 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Cinoxacin (Compound 64716), a synthetic antimicrobial related to the quinolone class of orally active antibacterial agent. Cinoxacin has antibacterial activity against many gram-negative aerobic bacteria and inhibits bacterial DNA synthesis. Cinoxacin can be used for the research of urinary tract infections and bacterial prostatitis^{[1][2]}.

IC₅₀ & Target

Quinolone

In Vitro

Cinoxacin (0-200µg/mL approximately, 3-24 h) inhibits many gram-negative aerobic bacteria with MIC values ranging from 4 to 64 µg/mL^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line: Gram-negative aerobic bacteria (Escherichia coli, Proteus sp. etc.)

Concentration: 0-200µg/mL approximately

	Incubation Time:	3-24 h
	Result:	Inhibited basal cell proliferation (40% in FB-2 and 35% in WRO) at 10 μ M, inhibited cell number (by 68% to 73%) at 40 and 60 μ M).
In Vivo	Cinoxacin (Oral administration, 1.7 g/kg, treated at 1 and 5 h postinfection) is effective in experimental bacterial infections in mice, with ED ₅₀ values ranging from 8.1 to 58.6 mg/kg ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Indicated bacterial infected mice model ^[2]
	Dosage:	1.7 g/kg, treated at 1 and 5 h postinfection
	Administration:	Oral administration
	Result:	Displayed antibacterial activity with ED ₅₀ values ranging from 8.1 to 58.6 mg/kg.

CUSTOMER VALIDATION

- J Chem Inf Model. 2021 Jul 21.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Scavone JM, et al. Cinoxacin: mechanism of action, spectrum of activity, pharmacokinetics, adverse reactions, and therapeutic indications. *Pharmacotherapy*. 1982 Sep-Oct;2(5):266-72.
- [2]. W E Wick, et al. Compound 64716, a new synthetic antibacterial agent. *Antimicrob Agents Chemother*. 1973 Oct;4(4):415-20.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA